BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl Androl Urol 2021;10:1506-20. [PMID: 33850785 DOI: 10.21037/tau-20-1150] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
Number Citing Articles
1 Mohanty SK, Lobo A, Cheng L. The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol 2022:S0046-8177(22)00224-6. [PMID: 36084769 DOI: 10.1016/j.humpath.2022.08.006] [Reference Citation Analysis]
2 Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and Prevention of Renal Cell Carcinoma. Cancers (Basel) 2022;14:4059. [PMID: 36011051 DOI: 10.3390/cancers14164059] [Reference Citation Analysis]
3 Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol 2022. [PMID: 35896615 DOI: 10.1038/s41379-022-01108-5] [Reference Citation Analysis]
4 Angori S, Lobo J, Moch H. Papillary renal cell carcinoma: current and controversial issues. Curr Opin Urol 2022;32:344-51. [PMID: 35674688 DOI: 10.1097/MOU.0000000000001000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kang Z, Yang J. Construction and validation of an autophagy-related long non-coding RNA signature to predict the prognosis of kidney renal papillary cell carcinoma. J Investig Med 2022:jim-2022-002379. [PMID: 35725019 DOI: 10.1136/jim-2022-002379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Pohl L, Friedhoff J, Jurcic C, Teroerde M, Schindler I, Strepi K, Schneider F, Kaczorowski A, Hohenfellner M, Duensing A, Duensing S. Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. Front Oncol 2022;12:889686. [PMID: 35619925 DOI: 10.3389/fonc.2022.889686] [Reference Citation Analysis]
7 Iannantuono GM, Riondino S, Sganga S, Roselli M, Torino F. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. Int J Mol Sci 2022;23:3995. [PMID: 35409355 DOI: 10.3390/ijms23073995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lobo J, Ohashi R, Helmchen BM, Rupp NJ, Rüschoff JH, Moch H. The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth. Biomedicines 2021;9:1418. [PMID: 34680535 DOI: 10.3390/biomedicines9101418] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Montironi R, Lopez-Beltran A, Cimadamore A, Cheng L, Scarpelli M. What's the future in uropathology. Urologia 2021;88:265-6. [PMID: 34612741 DOI: 10.1177/03915603211049884] [Reference Citation Analysis]
10 Peired AJ, Campi R, Angelotti ML, Antonelli G, Conte C, Lazzeri E, Becherucci F, Calistri L, Serni S, Romagnani P. Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. Cancers (Basel) 2021;13:4588. [PMID: 34572815 DOI: 10.3390/cancers13184588] [Cited by in F6Publishing: 5] [Reference Citation Analysis]